Skip to main content
. 2022 May 2;30(8):6641–6648. doi: 10.1007/s00520-022-07090-7

Table 1.

Patient characteristics

20-min PICT (n = 46) 45-min PICT (n = 45) 90-min PICT (n = 723)
Age (mean, SD) 57 (11.1) 58 (13.7) 57 (12.1)

   Gender

   Female

 42 (91%) 44 (98%) 723 (97%)

Cancer

   Breast

   Ovarian

   Endometrial

   Lung

   Other

Paclitaxel dosage

   70 mg/m2

   80 mg/m2

   90 mg/m2

29 (63%)

7 (15%)

3 (7%)

4 (9%)

3 (7%)

1 (2%)

39 (85%)

6 (13%)

33 (73%)

5 (11%)

2 (4%)

2 (4%)

3 (7%)

1 (2%)

41 (91%)

3 (7%)

596 (82%)

67 (9%)

6 (1%)

2 (< 1%)

52 (7%)

3 (< 1%)

572 (79%)

148 (20%)

Treatment

   Paclitaxel monotherapy

   Combination chemotherapy

   Combination monoclonal antibodies

   Combination chemotherapy + monoclonal antibodies

Setting

   (Neo) adjuvant

   Palliative

14 (30%)

6 (13%)

13 (28%)

12 (26%)

21 (46%)

25 (54%)

14 (30%)

8 (17%)

13 (28%)

11 (24%)

24 (53%)

21 (47%)

505 (70%)

106 (15%)

105 (15%)

7 (1%)

215 (30%)

503 (70%)
Number of cycles with scalp-cooling (mean, SD) 11.0 (6.8) 10.0 (5.4) 10.0 (5.5)

PICT Post-infusion cooling time, SD standard deviation

*Frequencies (%), some percentages may not total 100 because of rounding